Balamurali Krishna Ambati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Balamurali Krishna Ambati has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Hironori Uehara
Moran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA
11 shared publicationsBonnie Archer
Phil and Penny Knight for Accelerating Scientific Impact, University of Oregon, Eugene, OR
8 shared publications- Subrata Kumar Das
School of Biomedical Engineering and Health Sciences, Shobhit Institute of Engineering and Technology, NH 58, Meerut 250110, India
6 shared publications Xiaohui Zhang
Ambati Lab, John A. Moran Eye Center, Salt Lake City, UT, USA; Department of Ophthalmology & Visual Sciences, University of Utah, Salt Lake City, UT, USA
5 shared publications- Brian C. Stagg
Moran Eye Center, University of Utah, Salt Lake City, Utah, USA
4 shared publications - Xiaohui Zhang
Dept. of Ophthalmology, Moran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT, 84132, United States
4 shared publications
Latest Publications
- 10 December 2025
- Published by Wolters Kluwer Health in Cornea
- Vol. 45 (5) , 658-666
Brillouin Optical Spectroscopy for In Vivo and Ex Vivo Assessment of Corneal Biomechanics
Purpose: Corneal ectasias, such as keratoconus, exhibit altered corneal shape, structure, and biomechanics. Patients would greatly benefit from volumetric, 3-dimensional, and regional measurements of corneal stiffness for early detection and post-treatment monitoring. Current methods use indirect measurements, confounded by intraocular pressure, corneal thickness, describing a global picture of the cornea, and fail to identify crucial early localized changes. We tested the Brillouin Optical Scanner System (BOSS), which uses the Brillouin principle for noncontact focal measurement of compressibility and corneal stiffness, expressed as the 3-dimensional Brillouin Longitudinal Modulus. Methods: We measured compressibility/corneal stiffness in 3-month and 10-month-old New Zealand white rabbits (n = 2; male = 1; female = 1). Rabbits remained awake, calm, and nonsedated. We separately analyzed ex vivo porcine corneas using BOSS (n = 28) and strip extensiometry (n = 13). The BOSS parameters were optimized for both sets of analyses. Results: The BOSS demonstrated precise measurements in in vivo rabbits and ex vivo porcine corneas with a <2% and <4% variation from the mean. All rabbit corneas (n = 4) showed an increase in Brillouin values, demonstrating an increase in corneal stiffness over 7 months, in vivo. Conclusions: The BOSS is capable of precise measurements and detecting subtle changes in corneal stiffness in the rabbits. The high precision and accuracy of biomechanical measurements in nonsedated rabbits will enable a reduction in preclinical animal numbers, especially for time course studies. Importantly, the ability of the BOSS to provide spatial biomechanical measurements makes it a valuable tool for early detection of asymmetric corneal ectasias and keratoconus.
- 10 December 2025
- Published by Wolters Kluwer Health in Cornea
- Vol. 45 (5) , 658-666
Brillouin Optical Spectroscopy for In Vivo and Ex Vivo Assessment of Corneal Biomechanics
Purpose: Corneal ectasias, such as keratoconus, exhibit altered corneal shape, structure, and biomechanics. Patients would greatly benefit from volumetric, 3-dimensional, and regional measurements of corneal stiffness for early detection and post-treatment monitoring. Current methods use indirect measurements, confounded by intraocular pressure, corneal thickness, describing a global picture of the cornea, and fail to identify crucial early localized changes. We tested the Brillouin Optical Scanner System (BOSS), which uses the Brillouin principle for noncontact focal measurement of compressibility and corneal stiffness, expressed as the 3-dimensional Brillouin Longitudinal Modulus. Methods: We measured compressibility/corneal stiffness in 3-month and 10-month-old New Zealand white rabbits (n = 2; male = 1; female = 1). Rabbits remained awake, calm, and nonsedated. We separately analyzed ex vivo porcine corneas using BOSS (n = 28) and strip extensiometry (n = 13). The BOSS parameters were optimized for both sets of analyses. Results: The BOSS demonstrated precise measurements in in vivo rabbits and ex vivo porcine corneas with a <2% and <4% variation from the mean. All rabbit corneas (n = 4) showed an increase in Brillouin values, demonstrating an increase in corneal stiffness over 7 months, in vivo. Conclusions: The BOSS is capable of precise measurements and detecting subtle changes in corneal stiffness in the rabbits. The high precision and accuracy of biomechanical measurements in nonsedated rabbits will enable a reduction in preclinical animal numbers, especially for time course studies. Importantly, the ability of the BOSS to provide spatial biomechanical measurements makes it a valuable tool for early detection of asymmetric corneal ectasias and keratoconus.
- 29 August 2017
- Published by Springer Nature in International Ophthalmology
- Vol. 38 (5) , 2257-2266
Pediatric keratoconus: a review of the literature
Purpose To describe the epidemiology and prevalence, rates of progression, difference between adult and pediatric populations, and therapeutic approaches to pediatric keratoconus from documented literature. Methods A literature search was done on PubMed using key words including pediatric keratoconus, children with keratoconus, adult keratoconus, penetrating keratoplasty, corneal cross-linking and intracorneal ring segments. The literature was reviewed and reported to explore the key epidemiological differences between the pediatric and adult population with regards to presentation and treatment options. Results Pediatric keratoconus is more aggressive than adult keratoconus, which has been explained by structural differences in the cornea between both populations. High rates of progression were documented in pediatric populations. While corneal collagen cross-linking, intracorneal ring segments and penetrating keratoplasties have been used as therapies in the pediatric population, the literature overwhelmingly shows higher rates of failure and progression despite these measures as compared to adults. Conclusion Pediatric keratoconus is more aggressive than adult keratoconus, and current therapies used in adults may not be sufficient for the pediatric population.
- 29 August 2017
- Published by Springer Nature in International Ophthalmology
- Vol. 38 (5) , 2257-2266
Pediatric keratoconus: a review of the literature
Purpose To describe the epidemiology and prevalence, rates of progression, difference between adult and pediatric populations, and therapeutic approaches to pediatric keratoconus from documented literature. Methods A literature search was done on PubMed using key words including pediatric keratoconus, children with keratoconus, adult keratoconus, penetrating keratoplasty, corneal cross-linking and intracorneal ring segments. The literature was reviewed and reported to explore the key epidemiological differences between the pediatric and adult population with regards to presentation and treatment options. Results Pediatric keratoconus is more aggressive than adult keratoconus, which has been explained by structural differences in the cornea between both populations. High rates of progression were documented in pediatric populations. While corneal collagen cross-linking, intracorneal ring segments and penetrating keratoplasties have been used as therapies in the pediatric population, the literature overwhelmingly shows higher rates of failure and progression despite these measures as compared to adults. Conclusion Pediatric keratoconus is more aggressive than adult keratoconus, and current therapies used in adults may not be sufficient for the pediatric population.
- Open Access
- 1 April 2017
- Published by Elsevier in Ophthalmology
- Vol. 124 (4) , e42-e43
Re: Schwartz et al.: Intracameral antibiotics and cataract surgery: endophthalmitis rates, cost, and stewardship (Ophthalmology. 2016;123:1411-1413).
- 1 April 2017
- Published by Elsevier in Ophthalmology
- Vol. 124 (4) , e42-e43
Open AccessRe: Schwartz et al.: Intracameral antibiotics and cataract surgery: endophthalmitis rates, cost, and stewardship (Ophthalmology. 2016;123:1411-1413).
- Open Access
- 23 January 2017
- Published by Elsevier in Molecular Therapy
- Vol. 25 (7) , 1606-1615
Targeted Intraceptor Nanoparticle for Neovascular Macular Degeneration: Preclinical Dose Optimization and Toxicology Assessment
- 23 January 2017
- Published by Elsevier in Molecular Therapy
- Vol. 25 (7) , 1606-1615
Open AccessTargeted Intraceptor Nanoparticle for Neovascular Macular Degeneration: Preclinical Dose Optimization and Toxicology Assessment
- Top Cited Papers
- 1 September 2016
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 54, 64-102
Risk factors and biomarkers of age-related macular degeneration
- 1 September 2016
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 54, 64-102
Top Cited PapersRisk factors and biomarkers of age-related macular degeneration
- 1 April 2016
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 42 (4) , 515-519
Hydrogel ocular sealant for wound closure during intrastromal corneal ring segment implantation
We present a new technique for the sutureless closure of corneal incisions after intrastromal corneal ring segment (ICRS) insertion. Twelve eyes of 7 patients with keratoconus were treated at our institution by the same surgeon with femtosecond laser-assisted ICRS implantation followed by slit-incision closure with a hydrogel ocular sealant. A retrospective review of clinical characteristics was performed over a mean follow-up of 5 months and compared with previously published data on traditional methods for wound management after ICRS insertion. All visual, refractive, and topographic outcomes were within expected limits. No adverse events were observed. Hydrogel ocular sealant was deemed to be a safe, effective, and surgeon-friendly option for wound closure during ICRS implantation. None of the authors has a financial or proprietary interest in any material or method mentioned.
- 1 April 2016
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 42 (4) , 515-519
Hydrogel ocular sealant for wound closure during intrastromal corneal ring segment implantation
We present a new technique for the sutureless closure of corneal incisions after intrastromal corneal ring segment (ICRS) insertion. Twelve eyes of 7 patients with keratoconus were treated at our institution by the same surgeon with femtosecond laser-assisted ICRS implantation followed by slit-incision closure with a hydrogel ocular sealant. A retrospective review of clinical characteristics was performed over a mean follow-up of 5 months and compared with previously published data on traditional methods for wound management after ICRS insertion. All visual, refractive, and topographic outcomes were within expected limits. No adverse events were observed. Hydrogel ocular sealant was deemed to be a safe, effective, and surgeon-friendly option for wound closure during ICRS implantation. None of the authors has a financial or proprietary interest in any material or method mentioned.
- 14 November 2015
- Published by Springer Nature in International Ophthalmology
- Vol. 36 (4) , 493-498
Safety of undiluted intracameral moxifloxacin without postoperative topical antibiotics in cataract surgery
The objective of this study is to evaluate the safety of undiluted 0.5 % intracameral moxifloxacin for postoperative endophthalmitis prophylaxis in cataract surgery patients without the use of additional postoperative topical antibiotics. All phacoemulsification cataract surgeries performed by a single surgeon (B.A.) at the John A. Moran Eye Center from June 2012 to May 2015 were reviewed retrospectively. From June 2012 to April 2014, patients were given topical 0.5 % moxifloxacin postoperatively. From May 2014 to May 2015, all patients were given moxifloxacin intracamerally with no antibiotics postoperatively. The follow-up period was 1 month after surgery. Preoperative visual acuity and postoperative visual acuity, corneal edema, and anterior chamber reaction were recorded and compared between the two groups. 384 cataract surgeries were performed during the study period. None of the 384 eyes in the study developed endophthalmitis. Of those 384 eyes, 222 were included in the study for analysis based on the inclusion and exclusion criteria. 131 were part of the topical antibiotic group and 91 were part of the intracameral group. The differences in uncorrected visual acuity at 1 day postoperatively (p = 0.595) and best corrected visual acuity at 1 month postoperatively (p = 0.099) were not statistically significant. Differences in corneal edema (p = 0.370) and anterior chamber reaction (p = 0.069) at 1 day postoperatively and corneal edema (p = 0.512) and anterior chamber reaction (p = 0.512) at 1 month postoperatively were also not statistically significant. Undiluted 0.5 % moxifloxacin can be safely injected intracamerally following cataract surgery without additional postoperative antibiotic prophylaxis to prevent endophthalmitis without adverse effects on patient outcomes.
- 14 November 2015
- Published by Springer Nature in International Ophthalmology
- Vol. 36 (4) , 493-498
Safety of undiluted intracameral moxifloxacin without postoperative topical antibiotics in cataract surgery
The objective of this study is to evaluate the safety of undiluted 0.5 % intracameral moxifloxacin for postoperative endophthalmitis prophylaxis in cataract surgery patients without the use of additional postoperative topical antibiotics. All phacoemulsification cataract surgeries performed by a single surgeon (B.A.) at the John A. Moran Eye Center from June 2012 to May 2015 were reviewed retrospectively. From June 2012 to April 2014, patients were given topical 0.5 % moxifloxacin postoperatively. From May 2014 to May 2015, all patients were given moxifloxacin intracamerally with no antibiotics postoperatively. The follow-up period was 1 month after surgery. Preoperative visual acuity and postoperative visual acuity, corneal edema, and anterior chamber reaction were recorded and compared between the two groups. 384 cataract surgeries were performed during the study period. None of the 384 eyes in the study developed endophthalmitis. Of those 384 eyes, 222 were included in the study for analysis based on the inclusion and exclusion criteria. 131 were part of the topical antibiotic group and 91 were part of the intracameral group. The differences in uncorrected visual acuity at 1 day postoperatively (p = 0.595) and best corrected visual acuity at 1 month postoperatively (p = 0.099) were not statistically significant. Differences in corneal edema (p = 0.370) and anterior chamber reaction (p = 0.069) at 1 day postoperatively and corneal edema (p = 0.512) and anterior chamber reaction (p = 0.512) at 1 month postoperatively were also not statistically significant. Undiluted 0.5 % moxifloxacin can be safely injected intracamerally following cataract surgery without additional postoperative antibiotic prophylaxis to prevent endophthalmitis without adverse effects on patient outcomes.
- Open Access
- 4 September 2015
- Published by American Diabetes Association in Diabetes
- Vol. 64 (12) , 4247-4259
Intravitreal AAV2.COMP-Ang1 Prevents Neurovascular Degeneration in a Murine Model of Diabetic Retinopathy
Diabetic retinopathy (DR) is the leading cause of blindness in the working-age population in the U.S. The vision-threatening processes of neuroglial and vascular dysfunction in DR occur in concert, driven by hyperglycemia and propelled by a pathway of inflammation, ischemia, vasodegeneration, and breakdown of the blood retinal barrier. Currently, no therapies exist for normalizing the vasculature in DR. Here, we show that a single intravitreal dose of adeno-associated virus serotype 2 encoding a more stable, soluble, and potent form of angiopoietin 1 (AAV2.COMP-Ang1) can ameliorate the structural and functional hallmarks of DR in Ins2Akita mice, with sustained effects observed through six months. In early DR, AAV2.COMP-Ang1 restored leukocyte-endothelial interaction, retinal oxygenation, vascular density, vascular marker expression, vessel permeability, retinal thickness, inner retinal cellularity, and retinal neurophysiological response to levels comparable with nondiabetic controls. In late DR, AAV2.COMP-Ang1 enhanced the therapeutic benefit of intravitreally delivered endothelial colony-forming cells by promoting their integration into the vasculature and thereby stemming further visual decline. AAV2.COMP-Ang1 single-dose gene therapy can prevent neurovascular pathology, support vascular regeneration, and stabilize vision in DR.
- 4 September 2015
- Published by American Diabetes Association in Diabetes
- Vol. 64 (12) , 4247-4259
Open AccessIntravitreal AAV2.COMP-Ang1 Prevents Neurovascular Degeneration in a Murine Model of Diabetic Retinopathy
Diabetic retinopathy (DR) is the leading cause of blindness in the working-age population in the U.S. The vision-threatening processes of neuroglial and vascular dysfunction in DR occur in concert, driven by hyperglycemia and propelled by a pathway of inflammation, ischemia, vasodegeneration, and breakdown of the blood retinal barrier. Currently, no therapies exist for normalizing the vasculature in DR. Here, we show that a single intravitreal dose of adeno-associated virus serotype 2 encoding a more stable, soluble, and potent form of angiopoietin 1 (AAV2.COMP-Ang1) can ameliorate the structural and functional hallmarks of DR in Ins2Akita mice, with sustained effects observed through six months. In early DR, AAV2.COMP-Ang1 restored leukocyte-endothelial interaction, retinal oxygenation, vascular density, vascular marker expression, vessel permeability, retinal thickness, inner retinal cellularity, and retinal neurophysiological response to levels comparable with nondiabetic controls. In late DR, AAV2.COMP-Ang1 enhanced the therapeutic benefit of intravitreally delivered endothelial colony-forming cells by promoting their integration into the vasculature and thereby stemming further visual decline. AAV2.COMP-Ang1 single-dose gene therapy can prevent neurovascular pathology, support vascular regeneration, and stabilize vision in DR.
- 1 May 2015
- Published by Elsevier in Experimental Eye Research
- Vol. 134, 155-158
In vivo ZW800-microbead imaging of retinal and choroidal vascular leakage in mice
- 1 May 2015
- Published by Elsevier in Experimental Eye Research
- Vol. 134, 155-158
In vivo ZW800-microbead imaging of retinal and choroidal vascular leakage in mice